All Pharma News
US FDA declines to approve Supernus` Parkinson`s combination again

US FDA declines to approve Supernus` Parkinson`s combination again
REUTERS
09 Apr 2024
Share Share
Acorda Therapeutics Announces Nasdaq Delisting Notification

Acorda Therapeutics Announces Nasdaq Delisting Notification
BUSINESSWIRE
03 Apr 2024
Share Share
Acorda files for bankruptcy, inks $185M asset deal to Merz

Acorda files for bankruptcy, inks $185M asset deal to Merz
Zoey Becker FIERCE PHARMA
03 Apr 2024
Share Share
Acorda Cancels Q4 and Year End 2023 Earnings Conference Call

Acorda Cancels Q4 and Year End 2023 Earnings Conference Call
BUSINESSWIRE
01 Apr 2024
Share Share
Acorda and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement

Acorda and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement
BUSINESSWIRE
01 Apr 2024
Share Share
Biogen returns ex-U.S. rights of MS drug Fampyra to Acorda

Biogen returns ex-U.S. rights of MS drug Fampyra to Acorda
Kevin Dunleavy FIERCE PHARMA
12 Jan 2024
Share Share
Acorda to Regain Global Commercialization Rights to FAMPYRA® by January 2025

Acorda to Regain Global Commercialization Rights to FAMPYRA® by January 2025
BUSINESSWIRE
11 Jan 2024
Share Share
Acorda Therapeutics Reports Third Quarter 2023 Financial Results

Acorda Therapeutics Reports Third Quarter 2023 Financial Results
BUSINESSWIRE
13 Nov 2023
Share Share
Acorda Announces Biopas Laboratories Submission to Regulatory Agencies

Acorda Announces Biopas Laboratories Submission to Regulatory Agencies
BUSINESSWIRE
06 Nov 2023
Share Share
Acorda Third Quarter 2023 Update

Acorda Third Quarter 2023 Update
BUSINESSWIRE
06 Nov 2023
Share Share